| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ARID1A; BAF250; C1orf4; ELD; HOSA1; Osa homolog 1; OSA1 nuclear protein; SMARCF1; MRD14; p270; B120; BM029;;ARID1A |
| WB Predicted band size | 242 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human ARID1A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4条关于ARID1A抗体的参考文献示例(内容基于公开学术文献概括，具体细节请以原文为准)：
---
1. **文献名称**: *ARID1A mutations in ovarian clear cell carcinoma and their association with tumor immune microenvironment*
**作者**: Wiegand KC, et al.
**摘要**: 本研究利用ARID1A抗体(通过免疫组化)检测卵巢透明细胞癌中ARID1A蛋白表达缺失，发现其与ARID1A基因突变密切相关，且表达缺失与肿瘤微环境中免疫细胞浸润减少相关，提示其潜在治疗意义。
2. **文献名称**: *ARID1A loss in cancer: Towards mechanism-based precision medicine*
**作者**: Jones S, et al.
**摘要**: 综述了ARID1A在多种癌症(如子宫内膜癌、胃癌)中的突变频率及功能，强调ARID1A抗体在临床诊断中的应用(如免疫组化检测蛋白缺失)，并探讨其作为治疗靶点的潜力。
3. **文献名称**: *Prognostic significance of ARID1A deficiency in endometrial carcinoma*
**作者**: Guan B, et al.
**摘要**: 通过ARID1A抗体检测子宫内膜癌组织样本，发现约40%病例存在ARID1A表达缺失，且与高级别肿瘤、晚期分期及不良预后显著相关，支持其作为生物标志物的价值。
4. **文献名称**: *ARID1A inactivation in solid tumors: Role in epigenetic dysregulation and therapeutic vulnerability*
**作者**: Samartzis EP, et al.
**摘要**: 研究使用ARID1A抗体(Western blot/免疫荧光)验证基因敲除细胞系模型，证明ARID1A缺失导致染色质重塑异常，并增加肿瘤对PARP抑制剂的敏感性，为靶向治疗提供依据。
---
**提示**：以上为概括性内容，建议通过PubMed或Google Scholar搜索具体文献标题获取全文。若需实验用途的抗体引用，可参考抗体供应商(如CST、Abcam)官网提供的验证文献。
ARID1A (AT-rich interaction domain 1A) is a key subunit of the SWI/SNF chromatin remodeling complex, which regulates gene expression by modulating nucleosome positioning. As a tumor suppressor, ARID1A mutations or loss of expression are implicated in numerous cancers, including ovarian clear cell carcinoma, endometrial carcinoma, and gastric cancer. Antibodies targeting ARID1A are critical tools for investigating its biological functions and clinical associations. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression levels, subcellular localization, and correlations with tumor progression or treatment response.
Structurally, ARID1A contains a conserved N-terminal ARID domain for DNA binding and a C-terminal domain involved in protein interactions. Antibodies often recognize specific epitopes, such as the ARID domain (e.g., clone E9) or other regions (e.g., clone D2A5U), enabling detection of truncation mutations common in cancers. Loss of ARID1A expression, identified via these antibodies, has been linked to microsatellite instability, defective DNA repair, and altered immunotherapy responses. Recent studies also explore ARID1A's role in synthetic lethality with therapeutic targets like EZH2 or PARP inhibitors. However, antibody specificity requires validation, as homologous family members (e.g., ARID1B) may cross-react. Clinically, ARID1A IHC is emerging as a potential companion diagnostic for patient stratification in precision oncology.
×
